INTRODUCTION {#s1}
============

Liver cirrhosis is a troublesome problem for public health worldwide, with high occurrence rate and mortality \[[@R1]\]. Cirrhosis is an advance stage of chronic liver disease, due to chronic infection with hepatitis virus, alcohol abuse, fat accumulation, autoimmune and metabolic alterations \[[@R2], [@R3]\]. Various complications are frequently observed in cirrhosis patients, such as acute kidney injury, portal vein thrombosis, variable abdominal pain \[[@R4], [@R5]\]. Among the complications, bacterial infection is a leading cause for death \[[@R6]\]. Unfortunately, patients with liver cirrhosis are more easily to be infected by pathogens due to impaired immunity, consequently poor outcomes \[[@R7]--[@R9]\].

Bloodstream infection (BSI) is a serious problem in many hospitalized patients, and is referred as being primary without obvious infection source, or secondary, arising as a complication of infection elsewhere (such as pneumonia, urinary tract, skin and soft tissues, intra-abdominal, device-related, etc) \[[@R10]\]. BSI is a common complication in liver cirrhosis \[[@R11]\]. It was reported that the frequencies of BSI in cirrhosis patients were 10 times higher than that in the non-cirrhosis group \[[@R12]\]. Two major reasons may lead to the high occurrence of BSI in cirrhosis patients: dysregulated intestinal bacterial translocation and cirrhosis associated immune dysfunction (CAID) \[[@R13]\]. The abnormal intestinal barrier permeability, overgrowth of small intestinal bacterial, and immune dysfunction may promote the bacteria into the bloodstream, leading to BSI \[[@R14], [@R15]\]. BSI is significantly associated with prolonged hospital stay, faster development of liver disease, and low survival rate \[[@R7], [@R16]\]. A population-based cohort study indicated that BSI was a predictor for mortality in liver cirrhosis patients \[[@R17]\] The most common pathogens for BSI include gram-negative entericbacilli, anaerobes, and *Enterococcus spp.* \[[@R13]\]. In the previous studies, several studies reported the clinical characteristics of BSI patients. However, few studies described the specific characteristics of *Escherichia coli* BSI patients.

Timely and appropriately empirical antibiotic treatments are important for survival among BSI patients. Growing evidences have indicated that inappropriate antibiotic regimens are associated with increased mortality \[[@R18], [@R19]\]. Until now, the empirical antibiotics are still effective for infection treatments. However, its failure rate is increasing due to the growing prevalence of multidrug-resistant multidrug resistant (MDR) bacteria. MDR is defined as acquired non-susceptibility to at least one agent in three or more antimicrobial categories \[[@R20]\]. There are several common MDR, including extended-spectrum β-lactamase-producing bacteria (ESBL), methicillin-resistant *Staphylococcus aureus* (MRSA), etc \[[@R21]\]. ESBL productions is one of the major reasons for antibiotic resistance in *Escherichia coli*. Therefore, to investigate the association between ESBL status and clinical characteristics in liver cirrhosis patients presenting *Escherichia coli* BSI will be helpful to guide empirical therapy.

In the present study, we aimed to investigate the clinical characteristics and antibiotic management, as well as independent risk factors for *Escherichia coli* BSI in liver cirrhosis patients. The liver disease of the patients were evaluated by Child-Pugh and model for end-stage liver disease (MELD) scores. We investigated the clinical characteristics of patients according to ESBL status of pathogens and survival status within 30 days after BSI diagnosis as well as sites of acquisition infection.

RESULTS {#s2}
=======

Baseline characteristics of the study population {#s2_1}
------------------------------------------------

There were 288 eligible patients in the present study, with average age of 51.95 ± 11.71 years. The study population included 204 males and 84 females and their mean times for hospital admission was 2.76 ± 3.29. Among the recruited patients, 213 (73.96%), 29 (10.07%), 32 (11.11%) and 14 (4.86%) patients were diagnosed with viral cirrhosis, alcoholic cirrhosis, autoimmune cirrhosis cases, and cryptogenic cirrhosis, respectively. The majority of the patients were classed as Child-Pugh class B (98, 34.03%) and C (171, 59.37%), while only few of them were diagnosed with class A (19, 6.60%). 45 of the patients were admitted to intensive care unit (ICU) ward (15.63%) (Table [1](#T1){ref-type="table"}).

###### Baseline characteristics of the collected patients

  Characteristics                                                            Patients (*n* = 288, %)
  -------------------------------------------------------------------------- -------------------------
  Age (years)                                                                51.95 ± 11.71
  Gender (male/female)                                                       204 (70.83)/84 (29.17)
  Average times for hospital admission (times)                               2.76 ± 3.29
  Clinical characteristics of the patients within 2 years before admission   
  Frequencies of SBP (mean ± SD)                                             0.25 ± 0.70
  Frequencies of pneumonia (mean ± SD)                                       0.06 ± 0.31
  Frequencies of septicemia (mean ± SD)                                      0.04 ± 0.21
  Admission condition                                                        
  ICU admission (yes/no)                                                     45 (15.63)/243 (84.37)
  Pathogenesis of cirrhosis                                                  
  Viral                                                                      213 (73.96)
  Alcoholic                                                                  29 (10.07)
  Autoimmune                                                                 32 (11.11)
  Cryptogenic                                                                14 (4.86)
  Combined with hepatocellular carcinoma (yes/no)                            69 (23.96)/219 (76.04)
  Child-Pugh                                                                 
  A                                                                          19 (6.60)
  B                                                                          98 (34.03)
  C                                                                          171 (59.37)
  Mean MELD value                                                            16.84 ± 7.99
  Complication during hospital stay                                          
  HE (yes/no)                                                                57 (19.79)/231 (80.21)
  SBP (yes/no)                                                               141 (48.96)/147 (51.04)
  Pneumonia (yes/no)                                                         26 (9.03)/262 (90.97)
  Septic shock (yes/no)                                                      53 (18.40)/235 (81.60)
  BSI data                                                                   
  Unknown cause                                                              228 (79.17)
  Digestive tract                                                            31 (10.76)
  Vascular intervention operation                                            13 (4.51)
  Skin intervention operation                                                13 (4.51)
  HCC                                                                        3 (1.04)
  ESBLs (+/−)                                                                139 (48.26)/149 (51.74)
  Hospital-acquired BSI (yes/no)                                             173 (60.07)/115 (39.93)
  MELD at BSI                                                                15.79 ± 7.63
  Δ MELD (at BSI-baseline) (mean ± SD)                                       −1.04 ± 4.34
  Susceptibility to the firstly selected antibiotic (sensitive/resistant)    219 (76.04)/69 (23.96)
  Shiver (yes/no)                                                            85 (29.51)/203 (70.49)
  Chill (yes/no)                                                             51 (17.71)/237 (82.29)
  Maximum body temperature (°C)                                              39.16 ± 0.68
  Clinical outcomes                                                          
  Average duration in hospital (days)                                        23.93 ± 16.99
  Duration of infection (days)                                               15.20 ± 11.69
  Non-survivors                                                              34 (11.81)
  Improved                                                                   186 (64.58)
  Invalid                                                                    68 (23.61)
  MELD                                                                       16.12 ± 9.96
  Appropriate empiric therapy within 48 h                                    
  Yes                                                                        253 (87.85)
  No                                                                         35 (12.15)

Note: ICU: Intensive care unit; MELD: Model for end-stage liver diseases; HE: Hepatic encephalopathy; SBP: Spontaneous bacterial peritonitis; BSI: Bloodstream infections; ESBLs: Extended spectrum beta-lactamases; HCC: Hepatocellular carcinoma.

In addition, 60.07% (173/288) of the study subjects were diagnosed with hospital-acquired BSI. The source of BSI included primary infection with unknown cause (228, 79.17%), and secondary infection with digestive tract (31, 10.76%), vascular intervention operation (13, 4.51%), skin intervention operation (13, 4.51%) and HCC (3, 1.04%). 139 (48.26%) of the collected patients were diagnosed with ESBL positive (ESBL^+^), while 149 (51.74%) patients were confirmed with ESBL negative (ESBL^−^). The average infection time for the study subjects was 15.20 ± 11.69 days. 253 (87.85%) patients received appropriate empiric therapy within 48h after BSI diagnosis, while 35 (12.15%) patients were treated with inappropriate antibiotics. The average duration in hospital of the study subjects was 23.93 ± 16.99 days. 30 days after BSI diagnosis, the condition of 186 (64.85%) patients were significantly improved, while therapeutic approaches were invalid in 68 (23.61%) patients. Overall 34 patients were dead and the mortality was 11.81%. The clinical characteristics of the study population were listed in Table [1](#T1){ref-type="table"}.

Clinical effects of hospital-acquired BSI in cirrhosis patients with BSI {#s2_2}
------------------------------------------------------------------------

Among the collected patients, the prevalence of hospital acquired BSI was 60.07%. We evaluated the effects of sites of acquisition infection on clinical characteristics of the study population. Analysis results indicated that cirrhosis patients with hospital-acquired BSI had a longer hospital stay than those without hospital acquired BSI (*P* = 0.000). Moreover, the MELD score at the discharged was also significantly associated with hospital acquired BSI (*P* = 0.000) (Table [2](#T2){ref-type="table"}).

###### Comparison of clinical characteristics in the study population according to their acquisition sites of infections, 30-day survival status

  Factors                                             Acquisition sites of infections   30-day survival status                                           
  --------------------------------------------------- --------------------------------- ------------------------ ------- --------------- --------------- -------
  Child-Pugh                                                                                                     0.272                                   0.058
  A                                                   14                                5                                19              0               
  B                                                   54                                44                               90              8               
  C                                                   105                               66                               145             26              
  ESBL                                                                                                           0.118                                   0.829
  \+                                                  77                                62                               122             17              
  \-                                                  96                                53                               132             17              
  Hospital-acquired BSI                                                                                          \-                                      0.874
  yes                                                 \-                                \-                               153             20              
  no                                                  \-                                \-                               101             14              
  ICU admission                                                                                                  0.315                                   0.000
  yes                                                 24                                21                               30              15              
  no                                                  149                               94                               224             19              
  Pathogenesis of cirrhosis                                                                                      0.728                                   0.554
  viral                                               132                               81                               190             23              
  alcoholic                                           16                                13                               25              4               
  autoimmune                                          17                                15                               26              6               
  cryptogenic                                         8                                 6                                13              1               
  HCC                                                                                                            0.662                                   0.715
  yes                                                 43                                26                               60              9               
  no                                                  130                               89                               194             25              
  BSI source                                                                                                     0.496                                   0.006
  unknown cause                                       137                               91                               206             22              
  digestive tract                                     16                                15                               21              10              
  vascular intervention operation                     9                                 4                                12              1               
  skin intervention operation                         8                                 5                                12              1               
  HCC                                                 3                                 0                                3               0               
  HE                                                                                                             0.708                                   0.004
  yes                                                 33                                24                               44              13              
  no                                                  140                               91                               210             21              
  SBP                                                                                                            0.202                                   0.621
  yes                                                 90                                51                               123             18              
  no                                                  183                               64                               131             16              
  Pneumonia                                                                                                      0.873                                   0.000
  yes                                                 16                                10                               17              9               
  no                                                  157                               105                              237             25              
  Septic shock                                                                                                   0.234                                   0.000
  yes                                                 28                                25                               38              15              
  no                                                  145                               90                               216             19              
  Susceptibility to the firstly selected antibiotic                                                              0.693                                   0.493
  sensitive                                           133                               86                               61              10              
  resistant                                           40                                29                               193             24              
  Hospital stays (days)                               29.22 ± 18.14                     15.98 ± 11.12            0.000   24.29 ± 16.77   21.29 ± 18.60   0.335
  Clinical outcomes                                                                                              0.124                                   \-
  non-survivors                                       20                                14                               0               34              
  improved                                            105                               81                               186             0               
  invalid                                             48                                20                               68              0               
  MELD at admission                                   17.48 ± 8.22                      15.87 ± 7.57             0.094   16.23 ± 7.61    21.38 ± 9.31    0.000
  MELD at onset of BSI                                15.67 ± 7.3                       15.98/ ± 8.14            0.735   15.28 ± 7.21    19.62 ± 9.52    0.002
  Final MELD                                          17.83 ± 10.23                     13.54 ± 8.98             0.000   15.02 ± 8.82    24.35 ± 13.69   0.000
  Duration of infection (days)                        14.96 ± 12.20                     15.57 ± 10.93            0.663   12.29 ± 12.71   15.59 ± 11.52   0.122
  Appropriate empiric therapy within 48h                                                                         0.138                                   0.003
  yes                                                 153                               97                               226             24              
  no                                                  17                                18                               28              10              

Note: ICU: Intensive care unit; MELD: Model for end-stage liver diseases; HE: Hepatic encephalopathy; SBP: Spontaneous bacterial peritonitis; BSI: Bloodstream infections; ESBLs: Extended spectrum beta-lactamases; HCC: Hepatocellular carcinoma; Final MELD: detected at discharged.

Effects of ESBLs status on clinical characteristics based on study group {#s2_3}
------------------------------------------------------------------------

The patients were dived into two groups according to ESBL status of their isolates: ESBL^+^ (*n* = 139) and ESBL^−^ (*n* = 149). The prevalence of ESBL producing bacteria was 48.26%. We compared the clinical characteristics between the two groups. Analysis results indicated that ICU (*P* = 0.018) and MELD at onset of BSI (*P* = 0.035) were significantly associated with status of ESBL. In addition, we also found that liver cirrhosis patients infected by ESBL positive bacteria showed low sensitivity to firstly selected antibiotics (*P* = 0.017), moreover, ESBL infection was significantly correlated with inappropriate empiric therapy within 48 h (*P* = 0.049). Other factors were similar between the two groups (*P* \> 0.05 for all) (Table [3](#T3){ref-type="table"}).

###### Effects of infection characteristics on clinical symptoms among the study population

  Factors                                             ESBL status     MDR infection                                           
  --------------------------------------------------- --------------- --------------- ------- --------------- --------------- -------
  Child-Pugh                                                                          0.724                                   0.424
  A + B                                               55              62                      21              64              
  C                                                   84              87                      34              80              
  ESBL status                                                                         \-                                      0.000
  positive                                            \-              \-                      48              39              
  negative                                            \-              \-                      7               105             
  Hospital-acquired BSI                                                               0.118                                   0.774
  yes                                                 77              96                      32              87              
  no                                                  62              53                      23              57              
  ICU admission                                                                       0.018                                   0.005
  yes                                                 29              16                      16              18              
  no                                                  110             133                     39              126             
  Septic shock                                                                        0.898                                   0.052
  yes                                                 26              27                      15              22              
  no                                                  113             122                     40              122             
  Susceptibility to the firstly selected antibiotic                                   0.017                                   0.025
  sensitive                                           96              121                     36              116             
  resistant                                           43              28                      19              28              
  Clinical outcomes                                                                   0.973                                   0.840
  Non-survivors                                       17              17                      9               19              
  improved                                            89              97                      33              91              
  invalid                                             33              35                      13              34              
  MELD at admission                                   16.27 ± 8.27    17.37 ± 7.72    0.242   16.36 ± 7.53    17.44 ± 8.35    0.406
  MELD at onset of BSI                                14.81 ± 7.53    16.71 ± 7.64    0.035   15.16 ± 7.98    16.17 ± 7.24    0.396
  Final MELD                                          15.18 ± 9.95    16.99 ± 9.92    0.123   15.69 ± 9.70    17.23 ± 10.61   0.351
  Duration of infection (days)                        15.26 ± 11.13   15.15 ± 12.23   0.940   16.20 ± 12.21   12.07 ± 7.71    0.021
  Appropriate antibiotics within 48h                                                  0.049                                   0.011
  yes                                                 115             135                     41              128             
  no                                                  24              41                      14              16              

Note: MDR: Multi-drug resistance.

Drug susceptibility analysis {#s2_4}
----------------------------

In the present study, we compared drug susceptibility according to ESBL status of the isolated pathogens. The results demonstrated that the susceptibilities to cefoperazone (*P* = 0.000), ceftriaxone (*P* = 0.000), cefepime (*P* = 0.000), cefotaxime (*P* = 0.000), ceftazidime (*P* = 0.000), levofloxacin (*P* = 0.000), gatifloxacin (*P* = 0.022), piperacillin (*P* = 0.000), SMZCO (*P* = 0.000), aztreonam (*P* = 0.000), fosfomycin (*P* = 0.023), furadantin (*P* = 0.025), ticarcillin/clavulanate potassium (*P* = 0.016), and ampicillin (*P* = 0.000) were significantly influenced by ESBL status. On the other side, ESBL status were not correlated with resistance to cefoperazone-sulbactam, cefmetazon, meropenem, amikacin, minocycline, and piperacillin/tazobactam (*P* \> 0.05 for all) (Table [4](#T4){ref-type="table"}). It was worth noting that among the isolated bacteria, two of them showed resistant to carbapenems antibiotics, which confirmed as carbapenems resistant Enterobacteriaceae (CRE) with the prevalence of 1.83%. The carbapernems resistant bacteria increased the difficulty of antibiotic management.

###### Comparison of drug resistance between ESBL positive and negative bacteria

  Antibiotics                         ESBL (+)   ESBL (--)      *P* value                
  ----------------------------------- ---------- -------------- ----------- ------------ -------
  Cefoperazone                        83         48 (57.83)     44          4 (9.10)     0.000
  Cefperazone-Sulbactam               84         2 (2.38)       66          0 (0.00)     0.207
  Ceftriaxone                         107        107 (100.00)   82          7 (8.54)     0.000
  Cefmetazon                          88         3 (3.40)       70          0 (0.00)     0.119
  Cefepime                            107        58 (54.20)     82          5 (6.10)     0.000
  Cefotaxime                          25         24 (96.00)     15          0 (0.00)     0.000
  Ceftazidime                         108        72 (66.67)     84          7 (8.33)     0.000
  Levofloxacin                        107        66 (61.68)     83          22 (26.51)   0.000
  Gatifloxacin                        24         17 (70.83)     15          5 (33.33)    0.022
  Imipenem                            109        2 (1.83)       83          0 (0.00)     0.215
  Meropenem                           103        1 (0.97)       81          0 (0.00)     0.374
  Amikacin                            108        3 (2.78)       81          1 (1.23)     0.466
  Piperacillin                        60         58 (96.67)     52          26 (50.00)   0.000
  Minocycline                         26         9 (34.61)      16          2 (12.50)    0.113
  SMZCO                               109        88 (80.73)     82          47 (57.32)   0.000
  Aztreonam                           107        72 (67.29)     82          4 (4.88)     0.000
  Fosfomycin                          68         9 (13.23)      54          1 (1.85)     0.023
  Furadantin                          84         9 (10.71)      66          1 (1.51)     0.025
  Ticarcillin/Clavulanate Potassium   93         50 (53.76)     69          24 (34.78)   0.016
  Piperacillin/tazobactam             107        7 (6.54)       84          1 (1.19)     0.067
  Ampicillin                          106        103 (97.17)    78          53 (67.95)   0.000

Based on their resistance to antibiotics, 27.5% of the isolated bacteria were confirmed as MDR pathogens. We investigated the association between MDR and clinical characteristics. The results suggested that ESBL status (*P* = 0.000), ICU admission (*P* = 0.005), susceptibility to the firstly selected antibiotic (*P* = 0.025), appropriate empiric therapy within 48h (*P* = 0.011), and duration of infection (*P* = 0.021) were significantly correlated with MDR. However, there were no statistic correlation between MDR and other characteristics (*P* \> 0.05 for all) (Table [3](#T3){ref-type="table"}).

Risk factors for 30-day mortality based on study population {#s2_5}
-----------------------------------------------------------

The clinical characteristics of survivors (*n* = 254) and non-survivors (*n* = 34) were compared in the study. The results demonstrated that ICU admission (*P* = 0.000), BSI sources (*P* = 0.006), hepatic encephalopathy (HE) (*P* = 0.004), pneumonia (*P* = 0.000), septic shock (*P* = 0.000), MELD at admission (*P* = 0.000), onset of BSI (*P* = 0.002), discharged (*P* = 0.000) and appropriate empiric therapy within 48 h (*P* = 0.003) were significantly different between survivors and non-survivors. In addition, other indexes did not influence the survival status (*P* \> 0.05 for all) (Table [2](#T2){ref-type="table"}).

Timely and appropriate antibiotic treatments were extremely important for survival in liver cirrhosis patients developing to BSI. Survival curve demonstrated that patients received appropriate empiric therapy within 48 h after BSI diagnosis had a significantly higher survival rate than those treated with inappropriate antibiotics (log rank test, *P* = 0.001) (Figure [1](#F1){ref-type="fig"}).

![Overall survival analysis for the study subjects according to therapeutic regimens\
The results demonstrated that patients who received appropriate antibiotic within 48 h had a higher survival than those treated with inappropriate antibiotics within 48 h (log rank test, *P* = 0.001).](oncotarget-09-35780-g001){#F1}

Cox regression model was applied to evaluate the risk factors for 30-day mortality among the collected patients. Univariate analyses indicated that appropriate empiric therapy within 48 h, ICU admission, HE, pneumonia, septic shock, MELD at onset of BSI and final MELD were significantly correlated with 30-day survival rate among the study population (*P* \< 0.05 for all). Multivariate analysis suggested that appropriate antibiotic treatment within 48 h (HR = 2.581, 95% CI = 1.166--5.715, *P* = 0.019), ICU admission (HR = 4.434, 95% CI = 2.130--8.823, *P* = 0.000), HE (HR = 2.379, 95% CI = 1.115--5.073, *P* = 0.025) and final MELD (HR = 1.074, 95% CI = 1.044--1.106, *P* = 0.000) were independent indicators for 30-day mortality in liver cirrhotic patients (Table [5](#T5){ref-type="table"}).

###### Risk factors for 30-day mortality in cirrhosis patients

  Factors                                                                 Univariate analyses    Multivariate analyses                          
  ----------------------------------------------------------------------- ---------------------- ----------------------- ---------------------- -------
  ESBL (positive vs negative)                                             0.943 (0.481--1.849)   0.864                   \-                     \-
  Hospital-acquired BSI (yes vs no)                                       1.006 (0.507--1.994)   0.987                   \-                     \-
  Sensitive to the firstly selected antibiotic (resistant vs sensitive)   1.608 (0766--3.379)    0.209                   \-                     \-
  Appropriate empiric therapy within 48 h (no vs yes)                     3.173 (1.514--6.647)   0.002                   2.581 (1.166--5.715)   0.019
  ICU admission (yes vs no)                                               4.578 (2.323--9.020)   0.000                   4.434 (2.130--8.823)   0.000
  Gender (male vs female)                                                 0.954 (0.456--1.995)   0.900                   \-                     \-
  Age                                                                     1.011 (0.982--1.041)   0.453                   \-                     \-
  Combined with HCC (yes vs no)                                           1.239 (0.578--2.658)   0.582                   \-                     \-
  HE (yes vs no)                                                          2.320 (1.161--4.635)   0.017                   2.379 (1.115--5.073)   0.025
  SBP (yes vs no)                                                         1.167 (0.594--2.294)   0.654                   \-                     \-
  Pneumonia (yes vs no)                                                   3.755 (1.750--8.054)   0.001                   \-                     \-
  Child-Pugh grade (C vs A+B)                                             2.165 (0.979--4.785)   0.056                   \-                     \-
  Septic shock (yes vs no)                                                3.116 (1.582--6.139)   0.001                   \-                     \-
  MELD at onset of BSI                                                    1.065 (1.019--1.114)   0.006                   \-                     \-
  Final MELD                                                              1.073 (1.044--1.102)   0.000                   1.074 (1.044--1.106)   0.000

Note: ICU: Intensive care unit; HE: Hepatic encephalopathy; MELD: Model for end-stage liver diseases; Final MELD: detected at discharged; -: indicated no related data.

DISCUSSION {#s3}
==========

Liver cirrhosis is a major healthy problems worldwide, and the critical complications resulted from cirrhosis are the leading reasons for ICU admission among the patients \[[@R22]\]. Liver cirrhosis can cause multiple organs failure, including liver, heart, lung, kidney, as well as immune systems \[[@R23]\]. Due to the functional disorder of the organs and immune system, patients with cirrhosis are susceptible to infections. BSI is a common complication for cirrhosis patients. In the present study, we evaluated the clinical characteristics and risk factors for mortality in liver cirrhosis patients with *Escherichia coli* BSI.

288 cirrhosis patients diagnosed with *Escherichia coli* BSI were collected in the present study. Among them, the occurrence rate of hospital-acquired BSI was 60.07%. We compared the clinical characteristics between hospital acquired BSI and non-hospital acquired BSI. The results suggested that patients with hospital-acquired BSI had a prolonged hospital stay. Related studies had indicated that hospital-acquired BSI could prolong hospital stay \[[@R24]\]. In addition, several studies indicated that hospital-acquired BSI was significantly associated with high mortality \[[@R25], [@R26]\]. However, no significant correlation between the sites of acquisition infection and mortality was found in the present study. The differences might be caused by the different medical conditions and pathogens. The effects of the sites of acquisition infection on clinical symptoms were needed to be well investigated in the next study.

ESBL production is one of the main cause for antimicrobial resistance in *Escherichia coli*, which is significantly correlated with therapeutic failures and high mortality \[[@R27], [@R28]\]. Unfortunately, the prevalence rate of ESBL positive bacteria is increasing. In the present study, 48.26% pathogens were confirmed as ESBL positive *Escherichia coli*. Drug sensitivity analysis demonstrated that these ESBL positive pathogen had a higher resistant rate to most of the common antibiotics, such as third-generation cephalosporin, quinolone. The liver cirrhosis patients infected by ESBL positive bacteria showed low sensitivity to the firstly selected antibiotics, and were more likely to undergo inappropriate empiric therapy within 48 h. Moreover, based on the drug sensitivity analysis, 27.5% pathogens were confirmed as MDR bacteria. Analysis results suggested that ESBL status, ICU admission, susceptibility to firstly selected antibiotic and appropriate empiric therapy within 48 h were significantly different between MDR infection and non-MDR infection. The result might reveal that patients infected by MDR pathogens were more likely to undergo antibiotic treatments failure and poor survival. It was worthy noting that two of the isolated bacteria were confirmed as CRE in the present study. Currently, CRE became common with high mortality. Moreover, unlike other antibiotic resistance, carapenems resistance was a complex process and mediated by several mechanisms, leading to limited therapeutic effects based on the present antibiotics \[[@R29], [@R30]\]. Related studies reported that combination antibiotic treatments could significantly reduce the mortality in patients infected with CRE \[[@R31]\]. The optimal antibiotic treatment regimens for CRE were needed to be investigated in further studies.

Child-Pugh score and MELD score are based on the specific characteristics of cirrhosis. These scoring standards were simple and widely applied to predict long- and short-time mortality in liver cirrhosis patients, even among those combined with infection \[[@R32]\]. However, accumulating evidences demonstrated that besides of the general scores, the specific parameters about infection severity should also be used to predict outcomes in liver cirrhosis patients combined with BSI \[[@R33], [@R34]\]. In the current study, Cox regression model was used to evaluate the prognostic value of clinical parameters. The results suggested that empiric therapy within 48 h, ICU admission, HE and final MELD score were independent biomarkers for prognosis in liver cirrhosis patients presenting *Escherichia coli* BSI. In the previous studies, several factors were confirmed as prognostic markers for liver cirrhosis patients combined with BSI, including MELD score, SBP as BSI source, appropriate antibiotic treatments, HE, and so on \[[@R35], [@R36]\]. All these indicators could help identify the high-risk individuals as soon as possible, thereby the therapeutic regimens were adjusted to improve clinical outcomes. It was noted that cirrhosis patients who were admitted to ICU, with high MELD or presented HE had a complex disease process and several factors might contribute to their mortality besides of infection. Therefore, novel prognostic systems combined with general and specific characteristics were needed to predict prognosis in liver cirrhosis patients combined with *Escherichia coli* BSI.

In conclusion, ESBL production is an important influencing factor for antibiotic resistance in *Escherichia coli* and patients carrying ESBL producing pathogens are more likely admitted to ICU ward, with worse MELD score. In addition, ICU admission, HE, MELD score and empiric therapy within 48h are independent predictors for outcomes in cirrhosis patients with *Escherichia coli* BSI. The present study may be useful for therapy of *Escherichia coli* BSI in patients with liver cirrhosis.

MATERIALS AND METHODS {#s4}
=====================

Study subjects {#s4_1}
--------------

The present study was a retrospective and observational study. The liver cirrhosis patients developing to *Escherichia coli* BSI during the period of hospitalization in Beijing 302 Hospital from May 2009 to September 2014 were collected in the study. The collected patients should meet the following criterion: (1) The study subjects were adult group; (2) All of the patients were diagnosed with decompensated liver cirrhosis; (3) All of the patients were infected with single *Escherichia coli.* And no other pathogens were isolated from the infection specimens; (4) The clinical characteristics of the patients were available. For cases who developed multiple BSIs during the study period, only the first BSI episode was included in the analysis.

Data collection {#s4_2}
---------------

The collected patients were pathologically diagnosed with liver cirrhosis and presented BSI during the study period. The demographics characteristics including gender and age, hospitalization information, pathogenesis and severity degree of the disease according to Child-Pugh and MELD scores \[[@R37], [@R38]\], complications during the hospital stay, baseline characteristics of BSI, and outcomes at discharged were recorded in the present study. In addition, the results of drug sensitivity test and empirical antibiotic regimen were also recorded. 30-day mortality was used to measure the primary outcomes of the collected patients. The patients developed BSI over 48 h after hospital admission were considered as hospital acquired. MELD scores were respectively recorded at the time of hospital admission, onset of infection and discharged.

Antimicrobial susceptibility testing {#s4_3}
------------------------------------

Antimicrobial susceptibility of ESBL producing *Escherichia coli* isolates tested by disk diffusion method and interpreted according to Clinical Laboratories Standards Institute (CLSI) criteria \[[@R39]\]. The antimicrobials tested were cefoperazone, ceftriaxone, cefepime, cefotaxime, ceftazidime, levofloxacin, gatifloxacin, piperacillin, SMZCO, aztreonam, fosfomycin, furadantin, ticarcillin/clavulanate potassium potassiumand, ampicillin, cefoperazone-sulbactam, cefmetazon, meropenem, amikacin, minocycline, and piperacillin/tazobactam. *Escherichia coli* ATCC 25922 were used as negative control. The isolates that were resistant to three or more antimicrobial from different classes were defined as MDR.

Statistical analysis {#s4_4}
--------------------

The continuous variables were presented as mean ± SD and analyzed by student's *t* test. Chi-square test was applied to analyze the categorical variables. The clinical characteristics of the collected patients were compared according to the sites of acquisition infection, survival status, as well as the status of ESBLs of their blood cultures. Kaplan-Meier curve was performed to assess the survival of patients with different antibiotics treatment. Cox regression analysis was used to evaluate the independent risk factors for 30-day BSI mortality in cirrhotic patients. The analyses were performed with SPSS 18.0 software (SPSS Inc., Chicago, IL, USA) and *P* value less than 0.05 was considered statistically significant.
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